Multiple Sclerosis - Pipeline Review, H2 2017

  • ID: 4438385
  • Drug Pipelines
  • 780 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 2-BBB Medicines BV
  • Athersys Inc
  • Compugen Ltd
  • ImmuneTarget Inc
  • Merck KGaA
  • ReceptoPharm Inc
  • MORE
Multiple Sclerosis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H2 2017, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 10, 27, 29, 161, 35 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 4 and 48 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 2-BBB Medicines BV
  • Athersys Inc
  • Compugen Ltd
  • ImmuneTarget Inc
  • Merck KGaA
  • ReceptoPharm Inc
  • MORE
Introduction

Multiple Sclerosis - Overview

Multiple Sclerosis - Therapeutics Development

Multiple Sclerosis - Therapeutics Assessment

Multiple Sclerosis - Companies Involved in Therapeutics Development

Multiple Sclerosis - Drug Profiles

Multiple Sclerosis - Dormant Projects

Multiple Sclerosis - Discontinued Products

Multiple Sclerosis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Multiple Sclerosis, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2 2017 (Contd..2), H2

Number of Products under Development by Companies, H2 2017 (Contd..3), H2

Number of Products under Development by Companies, H2 2017 (Contd..4), H2

Number of Products under Development by Companies, H2 2017 (Contd..5), H2

Number of Products under Development by Companies, H2 2017 (Contd..6), H2

Number of Products under Development by Companies, H2 2017 (Contd..7), H2

Number of Products under Development by Companies, H2 2017 (Contd..8), H2

Number of Products under Development by Companies, H2 2017 (Contd..9), H2

Number of Products under Development by Companies, H2 2017 (Contd..10), H2

Number of Products under Development by Companies, H2 2017 (Contd..11), H2

Number of Products under Development by Universities/Institutes, H2

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Products under Development by Companies, H2 2017 (Contd..4), H2

Products under Development by Companies, H2 2017 (Contd..5), H2

Products under Development by Companies, H2 2017 (Contd..6), H2

Products under Development by Companies, H2 2017 (Contd..7), H2

Products under Development by Companies, H2 2017 (Contd..8), H2

Products under Development by Companies, H2 2017 (Contd..9), H2

Products under Development by Companies, H2 2017 (Contd..10), H2

Products under Development by Companies, H2 2017 (Contd..11), H2

Products under Development by Companies, H2 2017 (Contd..12), H2

Products under Development by Companies, H2 2017 (Contd..13), H2

Products under Development by Companies, H2 2017 (Contd..14), H2

Products under Development by Companies, H2 2017 (Contd..15), H2

Products under Development by Universities/Institutes, H2

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Target, H2 2017 (Contd..1), H2

Number of Products by Stage and Target, H2 2017 (Contd..2), H2

Number of Products by Stage and Target, H2 2017 (Contd..3), H2

Number of Products by Stage and Target, H2 2017 (Contd..4), H2

Number of Products by Stage and Target, H2 2017 (Contd..5), H2

Number of Products by Stage and Target, H2 2017 (Contd..6), H2

Number of Products by Stage and Target, H2 2017 (Contd..7), H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H2

Multiple Sclerosis - Pipeline by 4D Pharma PLC, H2

Multiple Sclerosis - Pipeline by AB Science SA, H2

Multiple Sclerosis - Pipeline by AbbVie Inc, H2

Multiple Sclerosis - Pipeline by Abion Inc, H2

Multiple Sclerosis - Pipeline by Ablynx NV, H2

Multiple Sclerosis - Pipeline by Abzena Plc, H2

Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H2

Multiple Sclerosis - Pipeline by Actelion Pharmaceuticals Ltd, H2

Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2

Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H2

Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H2

Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2

Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H2

Multiple Sclerosis - Pipeline by Alkermes Plc, H2

Multiple Sclerosis - Pipeline by Allergan Plc, H2

Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H2

Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H2

Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H2

Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H2

Multiple Sclerosis - Pipeline by Antoxis Ltd, H2

List of Figures

Number of Products under Development for Multiple Sclerosis, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 2-BBB Medicines BV
  • 4D Pharma PLC
  • AB Science SA
  • AbbVie Inc
  • Abion Inc
  • Ablynx NV
  • Abzena Plc
  • Acorda Therapeutics Inc
  • Actelion Pharmaceuticals Ltd
  • Addex Therapeutics Ltd
  • Adhaere Pharmaceuticals Inc
  • Aegis Therapeutics LLC
  • Affectis Pharmaceuticals AG
  • AiCuris GmbH & Co KG
  • Alkermes Plc
  • Allergan Plc
  • Alpha Cancer Technologies Inc
  • Amarna Therapeutics BV
  • Anavex Life Sciences Corp
  • Antisense Therapeutics Ltd
  • Antoxis Ltd
  • Aphios Corp
  • Apitope International NV
  • ARA Healthcare Pvt Ltd
  • Arrien Pharmaceuticals LLC
  • Artielle ImmunoTherapeutics Inc
  • Arven Ilac
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Athersys Inc
  • Atlantic Bio Sci LLC
  • Axxam SpA
  • Baliopharm AG
  • Bio-Cancer Treatment International Ltd
  • BioApex sro
  • Biocad
  • Biocon Ltd
  • Biogen Inc
  • BioHealthonomics Inc
  • Bionovis SA
  • Bionure Farma SL
  • Biovista Inc
  • Bolder Biotechnology Inc
  • BrainStorm Cell Therapeutics Inc
  • Bristol-Myers Squibb Co
  • BTB Pharma AB
  • CASI Pharmaceuticals Inc
  • Celgene Corp
  • Cell Cure Neurosciences Ltd
  • Cell2B Advanced Therapeutics SA
  • Cinnagen Co
  • Cognosci Inc
  • Coherus BioSciences Inc
  • Commence Bio Inc
  • Complement Pharma BV
  • Compugen Ltd
  • Critical Outcome Technologies Inc
  • CuraVac Inc
  • Cyxone AB
  • DanDrit Biotech A/S
  • Denceptor Therapeutics Ltd
  • Eli Lilly and Co
  • Evgen Pharma Plc
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Flex Pharma Inc
  • Forward Pharma AS
  • FPRT Bio Inc
  • Gemac SA
  • Genervon Biopharmaceuticals LLC
  • GeNeuro SA
  • Genzyme Corp
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glialogix Inc
  • Gliknik Inc
  • Hansa Medical AB
  • Harbor Therapeutics Inc
  • Humanigen Inc
  • Immune Response BioPharma Inc
  • ImmuneTarget Inc
  • Immungenetics AG
  • Immunwork Inc
  • Inception Sciences Inc
  • Inovio Pharmaceuticals Inc
  • Io Therapeutics Inc
  • Istesso Ltd
  • Johnson & Johnson
  • Jyant Technologies Inc
  • Kadimastem Ltd
  • Kadmon Corp LLC
  • KAHR medical Ltd
  • Karo Pharma AB
  • Karyopharm Therapeutics Inc
  • Kissei Pharmaceutical Co Ltd
  • KPI Therapeutics Inc
  • Kyorin Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • LFB SA
  • Lipocure Ltd
  • Longevity Biotech Inc
  • MacroGenics Inc
  • Mapi Pharma Ltd
  • Maruho Co Ltd
  • MedAnnex Ltd
  • MedDay SA
  • Medestea Research & Production SpA
  • MedImmune LLC
  • Merck KGaA
  • Meta-IQ ApS
  • Mitochon Pharmaceuticals Inc
  • Mitotech SA
  • Mitsubishi Tanabe Pharma Corp
  • Mochida Pharmaceutical Co Ltd
  • Momenta Pharmaceuticals Inc
  • MorphoSys AG
  • Mount Tam Biotechnologies Inc
  • Neuren Pharmaceuticals Ltd
  • Neurofx Inc
  • Neuronax SAS
  • New World Laboratories Inc
  • Novartis AG
  • Nuevolution AB
  • Numab Innovation AG
  • Ogeda SA
  • Omeros Corp
  • OncoImmune Inc
  • Oryzon Genomics SA
  • OSE Immunotherapeutics
  • Pangen Biotech Inc.
  • Parvus Therapeutics Inc
  • Pfenex Inc
  • Pfizer Inc
  • Pharmaxis Ltd
  • Principia Biopharma Inc
  • ProNoxis AB
  • Quimatryx SL
  • ReceptoPharm Inc
  • RedHill Biopharma Ltd
  • RegeneRx Biopharmaceuticals Inc
  • Renovo Neural Inc
  • Resverlogix Corp
  • ReveraGen BioPharma Inc
  • Rhizen Pharmaceuticals SA
  • Rigel Pharmaceuticals Inc
  • Rodos BioTarget GmbH
  • Rubius Therapeutics Inc
  • SanBio Inc
  • Santhera Pharmaceuticals Holding AG
  • Sareum Holdings Plc
  • Senju Pharmaceutical Co Ltd
  • Sorrento Therapeutics Inc
  • Synthon Holdings BV
  • Teikoku Pharma USA Inc
  • Teva Pharmaceutical Industries Ltd
  • TikoMed AB
  • Tiziana Life Sciences Plc
  • Toleranzia AB
  • TolerogenixX GmbH
  • Topas Therapeutics GmbH
  • TxCell SA
  • Vaccinex Inc
  • Vakzine Projekt Management GmbH
  • Vicore Pharma AB
  • viDA Therapeutics Inc
  • Yeda Research and Development Company Ltd
  • Yungjin Pharm Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll